sodium:4-[(1R,2R,3aS,8bS)-2-hydroxy-1-[(E,3S)-3-hydroxy-4-methyloct-1-en-6-ynyl]-2,3,3a,8b-tetrahydro-1H-cyclopenta[b][1]benzofuran-5-yl]butanoate
- CAS NO.：496807-11-5
- Empirical Formula: C24H31NaO5
- Molecular Weight: 422.5
- Update Date: 2024-07-02 08:55:11
![sodium:4-[(1R,2R,3aS,8bS)-2-hydroxy-1-[(E,3S)-3-hydroxy-4-methyloct-1-en-6-ynyl]-2,3,3a,8b-tetrahydro-1H-cyclopenta[b][1]benzofuran-5-yl]butanoate Structural](https://img.chemicalbook.in/CAS/20180601/GIF/496807-11-5.gif)
What is sodium:4-[(1R,2R,3aS,8bS)-2-hydroxy-1-[(E,3S)-3-hydroxy-4-methyloct-1-en-6-ynyl]-2,3,3a,8b-tetrahydro-1H-cyclopenta[b][1]benzofuran-5-yl]butanoate?
Biological Activity
Beraprost sodium, a prostacyclin analog, is a stable and orally active PGI2 prodrug. It is an effective vasodilator, which has the potential to study pulmonary hypertension by dilating renal blood vessels and improving microcirculation.
in vitro
Beraprost sodium (0.1, 1.0, and 10.0 μM; 24 hours) treatment leads to a significant increase in the number of tube formation, BPS plays an important role on angiogenic activity. Beraprost sodium (0.1, 1.0, and 10.0 μM; 24 hours) treatment let VE-cadherin at regions of cell–cell contact becomes more abundant and the morphology of endothelial cells tends to be normal compared with those cultured under hypoxia conditions.
< /b>
in vivo
Beraprost sodium (oral adminstration; 0.6 mg/kg; once daily; 3 or 7 days) can mitigate the development of renal interstitial fibrosis, decrease renal oxidative stress through its potential vasodilation effect, and further prevent renal interstitial fibrosis .
| Animal Model: | 6-8-week-old C57Bl/6J Male Mice |
| Dosage: | 0.6 mg/kg |
| Administration: | Oral adminstration; 0.6 mg/kg; once daily; 3 or 7 days |
| Result: < /td> | Mitigated the development of renal interstitial fibrosis. |
Storage
Store at -20°C
Properties of sodium:4-[(1R,2R,3aS,8bS)-2-hydroxy-1-[(E,3S)-3-hydroxy-4-methyloct-1-en-6-ynyl]-2,3,3a,8b-tetrahydro-1H-cyclopenta[b][1]benzofuran-5-yl]butanoate
| storage temp. | Store at -20°C |
| solubility | DMSO: 250 mg/mL (594.57 mM) |
| form | Solid |
| color | White to light yellow |
Safety information for sodium:4-[(1R,2R,3aS,8bS)-2-hydroxy-1-[(E,3S)-3-hydroxy-4-methyloct-1-en-6-ynyl]-2,3,3a,8b-tetrahydro-1H-cyclopenta[b][1]benzofuran-5-yl]butanoate
Computed Descriptors for sodium:4-[(1R,2R,3aS,8bS)-2-hydroxy-1-[(E,3S)-3-hydroxy-4-methyloct-1-en-6-ynyl]-2,3,3a,8b-tetrahydro-1H-cyclopenta[b][1]benzofuran-5-yl]butanoate
New Products
Indole Methyl Resin tert-butyl 9-methoxy-3-azaspiro[5.5]undecane-3-carboxylate Boc-His(Boc)-OH 2-CTC Resin 4-Chloro-7-tosy1-7Hpyrrolo[2,3-d]pyrimidine 5,7-Dibromo-1H-indole 2,5-dichloro-N-hydroxy-4,6-dimethylpyridine-3-carboximidamide 2,2-Dimethoxy-7-azaspiro[3.5]nonane hydrochloride 4-chloromethyl-5-methyl-1,3-dioxol-2-one (DMDO-Cl) R-2-BENZYLOXY PROPIONIC ACID 1,1’-CARBONYLDIIMIDAZOLE 1,1’-CARBONYLDI (1,2-4 TRIAZOLE) N-METHYL INDAZOLE-3-CARBOXYLIC ACID 4-((2-hydroxyethyl)thio)benzoic acid 1-(TERT-BUTOXYCARBONYL)-2-PYRROLIDINONE Methyl 6-methylnicotinate 3-Pyridineacrylic acid tert-Butyl carbazate TETRAHYDRO-2H-PYRAN-3-OL 2-((4-morpholinophenylamino) (methylthio) methylene) malononitrile 3-(4-morpholinophenylamino)-5-amino-1H-pyrazole-4-carbonitrile 2,4-dihydroxybenzaldehyde 1,3-Diethyl-1,3-Diphenylurea Methyl 2-methylquinoline-6-carboxylateRelated products of tetrahydrofuran
You may like
-
Pyridine 99.5% HPLC /UV SpectroscopyView Details
110-86-1 -
Guanine , 99%View Details
73-40-5 -
Piperazine Spot supply, best priceView Details
110-85-0 -
Potassium Hydroxide 90%View Details
1310-58-3 -
Dibutyl PhthalateView Details
84-74-2 -
Imidazole Spot supply, competitive priceView Details
288-32-4 -
Octadecyl 3-(3,5-di-tert-butyl-4-hydroxyphenyl)propionate 98% (GC)View Details
2082-79-3 -
Thiourea 99% ARView Details
62-56-6